These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27825169)

  • 1. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
    Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
    Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
    Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
    Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
    Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
    Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
    Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
    Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.
    Hoffman-Luca CG; Yang CY; Lu J; Ziazadeh D; McEachern D; Debussche L; Wang S
    PLoS One; 2015; 10(6):e0128807. PubMed ID: 26070072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.
    Lu J; McEachern D; Li S; Ellis MJ; Wang S
    Mol Cancer Ther; 2016 Dec; 15(12):2887-2893. PubMed ID: 27765850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
    Azmi AS; Philip PA; Aboukameel A; Wang Z; Banerjee S; Zafar SF; Goustin AS; Almhanna K; Yang D; Sarkar FH; Mohammad RM
    Curr Cancer Drug Targets; 2010 May; 10(3):319-31. PubMed ID: 20370686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy.
    Sun SH; Zheng M; Ding K; Wang S; Sun Y
    Cancer Biol Ther; 2008 Jun; 7(6):845-52. PubMed ID: 18340116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells.
    Kao CL; Hsu HS; Chen HW; Cheng TH
    Cancer Lett; 2009 Dec; 286(2):250-9. PubMed ID: 19560264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low expression of phosphatase and tensin homolog in clear‑cell renal cell carcinoma contributes to chemoresistance through activating the Akt/HDM2 signaling pathway.
    Chen J; Zhu H; Zhang Y; Cui MH; Han LY; Jia ZH; Wang L; Teng H; Miao LN
    Mol Med Rep; 2015 Aug; 12(2):2622-8. PubMed ID: 25954860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.
    Chen H; Luo D; Zhang L; Lin X; Luo Q; Yi H; Wang J; Yan X; Li B; Chen Y; Liu X; Zhang H; Liu S; Qiu M; Yang D; Jiang N
    Oncotarget; 2017 Jun; 8(26):43008-43022. PubMed ID: 28498808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
    Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
    Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.
    Azmi AS; Aboukameel A; Banerjee S; Wang Z; Mohammad M; Wu J; Wang S; Yang D; Philip PA; Sarkar FH; Mohammad RM
    Eur J Cancer; 2010 Apr; 46(6):1122-31. PubMed ID: 20156675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.
    Li M; Zhang Z; Hill DL; Wang H; Zhang R
    Cancer Res; 2007 Mar; 67(5):1988-96. PubMed ID: 17332326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.
    Shangary S; Qin D; McEachern D; Liu M; Miller RS; Qiu S; Nikolovska-Coleska Z; Ding K; Wang G; Chen J; Bernard D; Zhang J; Lu Y; Gu Q; Shah RB; Pienta KJ; Ling X; Kang S; Guo M; Sun Y; Yang D; Wang S
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3933-8. PubMed ID: 18316739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.